couter

Appian Corporation sells cloud-based process automation and AI-driven workflow solutions for enterprises, targeting industries like finance, healthcare, and logistics. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver on AI integration and revenue growth amid persistent margin pressures.

  • Appian’s cloud subscriptions revenue grew 25% YoY to $124.5M in Q1 2026, but net income remains negative.
  • The company has struggled to convert growth into profitability, with a net margin of -0.9% in the latest TTM period.
  • Institutional selling and skepticism about its AI moat have historically pressured the stock after earnings beats.

The Read

Appian’s stock has repeatedly fallen 12–14% after earnings beats and AI-driven guidance due to institutional selling, skepticism about its competitive moat, concerns over AI integration costs, and insufficient proof of enterprise adoption despite occasional rallies from strategic updates and insider buying.
Feb 9, 2027 — Q4 2026 Earnings Release
Chart by TradingView

The schedule

  • Tue9Feb

    The earnings release will test whether the company can deliver better-than-expected guidance and margin expansion, which would validate the recent AI integration efforts and cloud migration strategy.

  • Thu6May

    The Q1 2027 earnings release will test the company's ability to sustain growth from AI-driven product adoption and cloud migration, with a focus on revenue mix and operating margin expansion.

  • Thu22Jul

    The Q2 2027 earnings release will test the company's ability to maintain momentum from the AI product launches and cloud migration, with a focus on revenue growth and operating margin expansion.

Past

  • Sat10Oct

    Actual outcome: Bull · $51.94 at outcome

    APPN experienced a significant short-term price increase likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data may have exceeded expectations, improving investor sentiment and positioning the stock for further gains. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.9% from 2026-10-07 to 2026-10-21 (~2.1σ vs typical 10d vol). Target date 2026-10-20 reached; move through 2026-10-21 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +32.5% from 2026-10-08 (~2.4σ). Target date 2026-10-20 reached; move through 2026-10-22 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-23: +30.6% from 2026-10-09 (~2.2σ). Target date 2026-10-20 reached; move through 2026-10-23 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-28: +35.1% from 2026-10-14 (~2.6σ). Target date 2026-10-20 reached; move through 2026-10-28 observed.

    APPN experienced a significant short-term price increase likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data may have exceeded expectations, improving investor sentiment and positioning the stock for further gains. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.9% from 2026-10-07 to 2026-10-21 (~2.1σ vs typical 10d vol). Target date 2026-10-20 reached; move through 2026-10-21 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +32.5% from 2026-10-08 (~2.4σ). Target date 2026-10-20 reached; move through 2026-10-22 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-23: +30.6% from 2026-10-09 (~2.2σ). Target date 2026-10-20 reached; move through 2026-10-23 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-28: +35.1% from 2026-10-14 (~2.6σ). Target date 2026-10-20 reached; move through 2026-10-28 observed.

  • Tue15Sep

    Actual outcome: Bull · $37.96 at outcome

    The stock surged past the bull target following the Agent Studio Commercial Adoption Update, driven by strong commercial traction and positive momentum in converting pipeline into revenue. The update signaled progress in overcoming macro IT budget constraints, reinforcing investor confidence in the long-term growth trajectory of Appian's platform.

    Critical mid-quarter industry window assessing the timeline for Appian's Agent Studio to convert pipeline into recognized revenue against macro IT budget constraints, entering at $21.50.

  • Thu13Aug

    The earnings release will test whether the company can deliver better-than-expected guidance and margin expansion, differing from the last print where revenue growth was flat despite a positive surprise.

  • Thu14May

    Actual outcome: Bear · $21.37 at outcome

    Appian's Investor Day featured an $825 million mid-term revenue goal, an expanded share buyback program, and a focus on reliable AI in enterprise workflows. Although these strategic updates and subsequent insider buying drove an 11.2% rally following the event, the stock still closed at $21.37, remaining below the $22.00 bear floor. The positive momentum from the presentation was ultimately insufficient to fully offset the heavy downward pressure from the 19% plunge that followed its Q1 earnings release earlier in the month.

    Market will scrutinize Q2 cloud subscription momentum and potential mid-term financial goal expansions, evaluating whether recent multiple compressions represent a bottom.

  • Thu7May

    Actual outcome: Bear · $19.22 at outcome

    Despite Appian beating Q1 estimates—highlighted by a 25% year-over-year jump in cloud subscription revenue—and raising its full-year outlook, the stock plunged over 17%. The severe sell-off despite strong headline numbers was likely driven by broader pressures on software multiples and investor concerns over the high hidden costs of AI integration, which the CEO notably flagged as the 'elephant under the rug' shortly after the release.

  • Tue5May

    Actual outcome: Bear · $19.19 at outcome

    At the Appian World conference, the company showcased new capabilities in agentic automation and AI-assisted spec-driven development to transform complex workflows. However, these product and roadmap updates lacked the concrete financial metrics or enterprise adoption proof points needed to drive a significant breakout. As a result, the stock remained flat, trading between the bull and bear targets as the market awaits further evidence of AI-driven growth.

  • Thu19Feb

    Actual outcome: Bear · $25.14 at outcome

    Appian initially surged after beating Q4 estimates and issuing aggressive 2026 guidance driven by its new 'Agent Studio' AI platform. However, the stock failed to sustain these gains and fell below the bear floor by the run date, as significant institutional selling and broader market skepticism regarding its long-term competitive moat in the low-code AI space outweighed the positive headline results.